Page Image

Mantle Cell Lymphoma

The latest news, research, and perspectives in mantle cell lymphoma (MCL). In MCL, a malignant B lymphocyte in the outer edge, or mantle zone, of a lymph node follicle grows uncontrollably, resulting in the accumulation of lymphoma cells.

Advertisement
Advertisement
Patrick DalyMantle Cell Lymphoma | February 8, 2024
Liso-cel received regulatory acceptances from the US FDA and the Ministry of Health, Labour and Welfare in Japan for FL.
Read More
Blood Cancer TalksBlood Cancer Talks | January 31, 2024
Dr. Eyre and the hosts discuss lymphoma abstracts from ASH 2023, including the FLAIR trial and the SYMPATICO trial.
Melissa BadamoMantle Cell Lymphoma | December 18, 2023
Narazaciclib plus ibrutinib regulated signatures associated with DNA repair, P53 signaling, and glycolytic activity.
Michael Wang, MDMantle Cell Lymphoma | December 22, 2023
Progression-free survival was significantly prolonged with the combination compared with a placebo.
Melissa BadamoMantle Cell Lymphoma | December 15, 2023
The trial established the recommended phase II dose of acalabrutinib, venetoclax, and obinutuzumab.
Melissa BadamoMantle Cell Lymphoma | December 16, 2023
Compared to past studies, acalabrutinib plus rituximab improves post-chemotherapy induction CR rates and MRD negativity.
Melissa BadamoMantle Cell Lymphoma | December 15, 2023
The median overall survival was 44.9 months with ibrutinib plus venetoclax versus 38.6 months with ibrutinib plus placebo.
Leah SherwoodMantle Cell Lymphoma | December 14, 2023
The data came from ZUMA-2, a phase II, open-label, multicenter, single-arm trial in which participants received brexu-cel.
Melissa BadamoMantle Cell Lymphoma | December 13, 2023
The study evaluated ROR1 expression levels in a panel of MCL cell lines and primary patient samples.
Kerri FitzgeraldMantle Cell Lymphoma | December 13, 2023
Pirtobrutinib is a non-covalent (reversible) BTK inhibitor that inhibits both wild-type and C481-mutant BTK.
Kerri FitzgeraldMantle Cell Lymphoma | December 15, 2023
Study authors noted that the findings underscore the need for tailored approaches to MRD testing.
Melissa BadamoMantle Cell Lymphoma | December 13, 2023
Jonathon B. Cohen, MD, MS, reported these updated results from the BRUIN trial.
Melissa BadamoMantle Cell Lymphoma | December 6, 2023
Those high-risk disease features include high proliferation index, TP53 mutation, blastoid morphology, and CNS lymphoma.
Patrick DalyAggressive B-Cell Lymphoma | December 13, 2023
After a median of four years of follow-up, participants in the pivotal ZUMA-2 study had a median OS of nof nearly five years.
Blood Cancer TalksBlood Cancer Talks | December 5, 2023
Dr. Dickinson joins "Blood Cancer Talks" hosts to discuss phase I and II trials on DLBCL, follicular lymphoma, and more.
Patrick DalyMantle Cell Lymphoma | November 21, 2023
Mosunetuzumab plus polatuzumab vedotin achieved high CR rates in relapsed or refractory MCL with prior BTKi treatment.
Patrick DalyMantle Cell Lymphoma | November 21, 2023
Interspersing cytarabine in R-CHOP induction therapy did not yield significant improvements in elderly patients with MCL.
Patrick DalyMantle Cell Lymphoma | November 21, 2023
BOVen induced high rates of response and MRD-negativity among patients with untreated MCL with TP53 mutations.
Melissa BadamoMantle Cell Lymphoma | October 25, 2023
The study established the recommended phase II dose of ibrutinib combined with bortezomib.
Patrick DalyMantle Cell Lymphoma | October 24, 2023
Analysis of MCL tissue identified a immune-depleted tumor microenvironment subtype associated with treatment resistance.
Melissa BadamoMantle Cell Lymphoma | October 23, 2023
Brexu-cel was associated with improved OS compared with the standard of care (SOC) regimens, including bendamustine plus ...
Advertisement
Advertisement
Latest News

February 29, 2024